0 98

Cited 4 times in

Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer

Authors
 Rim S. Kim  ;  Nan Song  ;  Patrick G. Gavin  ;  Roberto Salgado  ;  Hanna Bandos  ;  Zuzana Kos  ;  Giuseppe Floris  ;  Gert G. G. M. Van den Eynden  ;  Sunil Badve  ;  Sandra Demaria  ;  Priya Rastogi  ;  Louis Fehrenbacher  ;  Eleftherios P. Mamounas  ;  Sandra M. Swain  ;  D. Lawrence Wickerham  ;  Joseph P. Costantino  ;  Soonmyung Paik  ;  Norman Wolmark  ;  Charles E. Geyer Jr  ;  Peter C. Lucas  ;  Katherine L. Pogue-Geile 
Citation
 JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, Vol.111(8) : 867-871, 2019 
Journal Title
 JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE 
ISSN
 0027-8874 
Issue Date
2019
Keywords
Breast cancer ; HER2 ; adjuvant trastuzumab ; prognosis ; tumor-infiltrating lymphocytes
Abstract
We retrospectively assessed association of stromal tumor-infiltrating lymphocytes (sTILs) with clinical outcomes and molecular variables reportedly predictive of trastuzumab-benefit in NSABP B-31 (N = 2,130). sTILs were assessed in 1,581 eligible B-31 cases utilizing all available H&E slides. Mean concordance between main reviewer and six other pathologists was 90.8% in 100 cases. Cox regressions were used to calculate hazard ratios (HRs). In chemotherapy and trastuzumab-added-to-chemotherapy arms, increases in sTILs, as a semi-continuous variable (combined arms HR = 0.42, 95% [CI]=0.27 to 0.64, two-sided P < 0.001) or as lymphocyte-predominant breast cancer (BC) with >50% sTILs (combined arms HR = 0.65, 95% CI = 0.49-0.86, two-sided P = 0.003), were statistically significantly associated with improved disease-free survival. There was no association of sTILs with trastuzumab-benefit. However, higher sTILs were statistically significantly associated with higher-trastuzumab-benefit groups by 8-gene prediction model (two-sided P < 0.001). Neither PIK3CA mutations nor Fc-gamma-receptor polymorphisms were associated with sTILs. sTILs may have utility as a prognostic biomarker identifying HER2-positive early-BC at low recurrence risk.
Full Text
https://academic.oup.com/jnci/article/111/8/867/5393262
DOI
10.1093/jnci/djz032
Appears in Collections:
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers
Yonsei Authors
Paik, Soon Myung(백순명) ORCID logo https://orcid.org/0000-0001-9688-6480
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/173504
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links